Summit Therapeutics
SMMT· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -2.0% in FY2025
Mahkam Zanganeh is the CEO of Summit Therapeutics and was paid $1.2M in FY2024 (Dec), down 94%.
Pay$100 in the stock at the end of FY20 → $2.5K
Executives3
See all- 1Manmeet S. SoniChief Operating Officer, Chief Financial Officer and DirectorFY2024
- 2Mahkam ZanganehCo-Chief Executive Officer, President and DirectorFY2024
- 3Robert W. DugganCo-Chief Executive Officer and ChairmanFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSummit Therapeutics paid CEO Robert W. Duggan $172.4K in FY2025 (Dec). No other named executive of that year is on file.
| Name | |||
|---|---|---|---|
| Robert W. DugganCo-Chief Executive Officer and Chairman | |||
| Manmeet S. SoniChief Operating Officer, Chief Financial Officer and Director | Not disclosed | ||
| Mahkam ZanganehCo-Chief Executive Officer, President and Director | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Summit Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Robert W. DugganChair · 6 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 17, 2026 | FY2025 |
| Annual report | 10-K | Feb 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Feb 24, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Feb 20, 2024 | FY2023 |
